

5th April 2016

ASX Announcement

Appointment to advise Consortium developing first in class, McGill University derived, novel biologic compound and biomarker.

iQ3Corp Ltd (ASX:iQ3) is pleased to announce that it has syndicated an investor consortium which include iQ Group Global entities, to enter into a joint venture to develop and commercialise a first in class oncology, novel biologic compound and biomarker. The intellectual property was originally developed at McGill University in Montreal Canada.

In addition, iQ3 has also been appointed to act as a lead advisor to the consortium and will prepare the joint venture for its next growth phase.

CEO Dr George Syrmalis stated “this is an incredible opportunity which gives Australian Life Science investors access to World Class Biotech assets and creates the opportunity to commercialize a significant novel compound which in this case also involves an accompanying biomarker. This is a strategically significant deal that iQ3 has advised on and signifies the important role we act in Australia’s drive for innovation.

It is expected that iQ3 will be realising further revenue, both in fees and equity, whilst contributing to Australia’s protagonistic role in the global life science arena”

Further information will be released to the markets in due course as the program progresses.

For more information, please feel free to contact the iQ3Corp Investor Relations Team.

Email:

investor.relations@iq3corp.com

Phone:

+61 2 8239 5400

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400

New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630

London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

About iQ3Corp Ltd:

iQ3Corp is a specialised life science corporate finance and advisory firm bridging capital with science to create the medicines of the future.

Disclaimer

Subject to any continuing disclosure obligations under the laws of the Commonwealth of Australia or the ASX listing rules, iQ3Corp Ltd (iQ3Corp or the Company) disclaims any perceived intent or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. Expressions such as 'believe', 'expect', 'anticipate', 'indicate', 'contemplate', 'target', 'plan', 'intends', 'continue', 'budget', 'estimate', 'may', 'will', 'schedule' and similar expressions identify forward-looking statements.

The following cautionary statements qualify all forward-looking statements made in this announcement. In particular, the direction and strategies adopted by iQ3Corp and detailed in this announcement represents the Company's strategic planning and decision-making practices and are based on current expectations. iQ3Corp's business is subject to uncertainties, risks and contingencies, many of which are outside the control of, and are presently unknown to the Company, and could cause the actual conduct, results, performance or achievements of iQ3Corp to vary in a material way from those expressed or implied in this announcement. Investors are cautioned that forward-looking statements are not guarantees of future performance or outcomes, and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Additional information concerning iQ3Corp's business, its associated risks and operations can be found in its periodic announcements to ASX.